Best reduction from baseline
in target lesions (%)
100
75
50
25
0
-25
-50
-75
-100
Patients
IPIlIMUMAB
19%
Best reduction from
baseline
in target lesions (%)
75
50
25
0
-25
-50
-75
-100
100
Patients
NIVOLUMAB
43.7%
Best reduction from
baseline
in target lesions (%)
100
75
50
25
0
-25
-50
-75
-100
NIVO + IPI
57.6%
Patients
Response to Treatment
Wolchok at al. ASCO 2016
